Engineered Living Materials Leave the Lab for the Field Robot
Engineered living materials fuse programmed microbes with composites to sense, report, and self-repair — and they are starting to ride on autonomous field robots.
Biotech & Health
Explore the frontier of life sciences and healthcare innovation. From breakthrough therapeutics and longevity research to the deep tech investments shaping tomorrow's treatments, discover the trends and breakthroughs redefining global health.
Posts tagged with Biotech & Health
Ziihera's First-Line GEA Bet: FDA Clears Jazz's HER2 Bispecific
FDA clears Ziihera (zanidatamab) as first-line HER2 therapy for advanced stomach cancer, the first bispecific to displace trastuzumab after 15 years.
Human Tissue, Printed in Orbit: Auxilium’s ISS Milestone Reshapes Biomanufacturing
Auxilium’s AMP-1 printed the first kidney and liver tissue ever made in orbit, pointing to orbital biomanufacturing for organoids and implants.
Carbon recycling at commercial scale: what LanzaTech's ethanol barge tells investors
LanzaTech's Steelanol plant ships ethanol made from steel-mill emissions at 80M litres a year. The carbon-recycling convergence is now commercial, but the margin still depends on policy.
Mango Materials turns waste methane into PHA. The scale question decides everything.
Mango Materials feeds waste methane to bacteria that make biodegradable PHA, carbon-negative on paper. The plant economics decide whether this scales.
Bio-ISRU: How Engineered Microbes Turn Space Resources Into Fuel, Food and Plastic
NASA and ESA are betting that engineered microbes can make fuel, food, plastics and medicine from local space resources — cutting launch mass by up to 85% versus hauling cargo from Earth.
DNA Data Storage Enters the Data Center: Inside Biomemory's Consolidation Bet
Hyunjun Park built the machines that write data into DNA, then ran out of runway. Paris rival Biomemory bought the pieces, and with a Scality partnership in hand it promises racks in real data centers this half. The physics case is settled. The money math is not.
The $77.5 Million Bet That Three Gut Transporters Can Retire the Dialysis Pill Routine
R1 Therapeutics debuted in March with an oversubscribed $77.5M Series A and one asset: AP306, a first-in-class phosphate-transporter inhibitor licensed out of Shanghai. Its phase 2a beat sevelamer head-to-head, and a global Phase 2b began July 21.